Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-05-05

FDA Approved: LAMIVUDINE — Supplemental Application (Apotex Corp.)

View source ↗

Summary

FDA approved a supplemental application for lamivudine by Apotex Corp., enabling the generic lamivudine product to be marketed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lamivudine (lamivudine)

Snippet

SUPPL AP for LAMIVUDINE (LAMIVUDINE)